Related Experiment Video
Updated: Mar 19, 2026
Modeling Paracrine Noncanonical Wnt Signaling In Vitro
Published on: December 10, 2021
Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in
Archita Ghoshal1, Siddhartha Sankar Ghosh2,3
1Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, 39, India.
Abstract:
The Wnt signaling pathway plays a predominant role in aberrant proliferation in myriad of cancers. In non-cancerous cells, Wnts are blocked by the secreted frizzled-related proteins (sFRPs) that are generally downregulated in cancer cells. We have purified and characterized bacterially expressed glutathione S-transferase-tagged SFRP4 from a novel clone generated from human cell origin. Cervical cancer (HeLa) and lung cancer (A549) cells, in which Wnt and associated genes were found to be expressed, were treated with the purified recombinant sFRP4, which revealed a significant dose-dependent cell growth inhibition up to 40 %. The current investigation on functionality of this bacterially produced recombinant sFRP4 in arresting cancer cell proliferation is the first of its kind, where G2/M phase arrest and early apoptosis were evident. Increase in phosphorylated β-catenin in sFRP4 treatment indicated inhibition of Wnt pathway, which was further confirmed by downregulation of pro-proliferative genes, namely cyclin D1, c-myc, and survivin. Functional activity of recombinant sFRP4 was further exploited in co-therapy module with chemotherapeutic drugs to decipher molecular events. Collectively, our study on purified recombinant sFRP4 from bacterial host holds great promise in targeting Wnt signaling for exploring new strategies to combat cancer.
Insights
Bacterially produced recombinant SFRP4 effectively inhibits cancer cell growth by blocking the Wnt signaling pathway. This novel approach shows promise for developing new cancer therapies targeting aberrant proliferation.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The Wnt signaling pathway is crucial in cancer cell proliferation.
- Secreted frizzled-related proteins (sFRPs) normally inhibit Wnt signaling but are downregulated in cancer.
- SFRP4 is a potential Wnt antagonist with therapeutic implications.
Purpose of the Study:
- To purify and characterize bacterially expressed recombinant SFRP4.
- To investigate the anti-proliferative effects of recombinant SFRP4 on cancer cells.
- To explore the potential of SFRP4 in combination cancer therapy.
Main Methods:
- Purification and characterization of glutathione S-transferase-tagged SFRP4 from a bacterial expression system.
- Treatment of cervical (HeLa) and lung (A549) cancer cells with recombinant SFRP4.
- Analysis of cell growth inhibition, cell cycle phase, apoptosis, and Wnt pathway markers (phosphorylated β-catenin, cyclin D1, c-myc, survivin).
Main Results:
- Recombinant SFRP4 demonstrated significant dose-dependent inhibition of cancer cell growth (up to 40%).
- SFRP4 treatment induced G2/M phase arrest and early apoptosis in cancer cells.
- Inhibition of the Wnt pathway was confirmed by increased phosphorylated β-catenin and downregulation of pro-proliferative genes.
Conclusions:
- Bacterially produced recombinant SFRP4 exhibits potent anti-cancer activity by inhibiting Wnt signaling.
- SFRP4 shows promise as a therapeutic agent for targeting cancer proliferation.
- Further investigation into SFRP4 co-therapy modules could lead to novel cancer treatment strategies.
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
02:54Canonical Wnt Signaling Pathway
01:41Non-Canonical Wnt Signaling Pathways
01:41Non-Canonical Wnt Signaling Pathways
01:16TGF - β Signaling Pathway
01:20The JAK-STAT Signaling Pathway